case_images: PMC6344168_01
case_images: Levels of CEA and CA125 throughout therapy. CA125 = OC125 antigen, CEA = carcinoembryonic antigen.
case_images: medi-98-e13924-g001.jpg
case_images: PMC6344168_01_medi-98-e13924-g001.jpg
case_images: F1
case_images: The tumor markers, carcinoembryonic antigen (CEA), and OC125 antigen (CA125) were rechecked and levels had dropped from 396.4 ng/mL to 67.90 ng/mL and from 20.63 U/mL to 8.28 U/mL respectively (Fig. 1). We found that the tumor marker levels had increased (Fig. 1), and an intracranial magnetic resonance imaging (MRI) showed multiple abnormally strengthened intracranial nodular shadows, suggesting metastasis (Figs. 5 and 6).
case_images: Computed tomography shows the mass in the left lung on mediastinal window before and after treatment.
case_images: medi-98-e13924-g002.jpg
case_images: PMC6344168_01_medi-98-e13924-g002.jpg
case_images: F2
case_images: Her computed tomography (CT) showed that the displacement of the left lung was significantly smaller than before (Figs. 2 and 3) and that the left iliac bone mass was reduced (Fig. 4).
case_images: Computed tomography shows the mass in the left lung on lung window before and after treatment.
case_images: medi-98-e13924-g003.jpg
case_images: PMC6344168_01_medi-98-e13924-g003.jpg
case_images: F3
case_images: Her computed tomography (CT) showed that the displacement of the left lung was significantly smaller than before (Figs. 2 and 3) and that the left iliac bone mass was reduced (Fig. 4).
case_images: The whole therapeutic process including apatinib and erlotinib, start time, dose titration, and treatment after progressive disease.
case_images: medi-98-e13924-g007.jpg
case_images: PMC6344168_01_medi-98-e13924-g007.jpg
case_images: F7
case_images: The entire therapy regimen is shown in Figure 7.